BEP regimen: Difference between revisions
No edit summary |
|||
(One intermediate revision by the same user not shown) | |||
Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[bleomycin]], [[etoposide]] and [[cisplatin|cisplatin(Platinol)]] used to treat advanced-stage ovarian and testicular germ-cell tumors.<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate = | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref> | {{PAGENAME}} refers to a regimen consisting of [[bleomycin]], [[etoposide]] and [[cisplatin|cisplatin(Platinol)]] used to treat advanced-stage ovarian and testicular [[Germ cell tumor|germ-cell tumors]].<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate = | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|B|Bleomycin}} | |||
{{chemo|E|Etoposide}} | |||
{{chemo|P|Cisplatin (Platinol)}} | |||
==Indications== | ==Indications== | ||
* [[ | * [[Germ cell tumor|Advanced-stage ovarian germ-cell tumors]]<ref name="pmid25559616">{{cite journal| author=Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y et al.| title=Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. | journal=Eur J Cancer | year= 2015 | volume= 51 | issue= 3 | pages= 340-51 | pmid=25559616 | doi=10.1016/j.ejca.2014.12.004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25559616 }} </ref> | ||
* [[ | * [[Germ cell tumor|Advanced-stage testicular germ-cell tumors]] | ||
==References== | ==References== |
Latest revision as of 14:22, 11 March 2015
WikiDoc Resources for BEP regimen |
Articles |
---|
Most recent articles on BEP regimen Most cited articles on BEP regimen |
Media |
Powerpoint slides on BEP regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on BEP regimen at Clinical Trials.gov Clinical Trials on BEP regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on BEP regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on BEP regimen Discussion groups on BEP regimen Patient Handouts on BEP regimen Directions to Hospitals Treating BEP regimen Risk calculators and risk factors for BEP regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for BEP regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: BEP; BEP Regimen; BEP regimen; Bleomycin-Etoposide-Platinol Regimen; PEB Regimen; Platinol-Etoposide-Bleomycin Regimen
Overview
BEP regimen refers to a regimen consisting of bleomycin, etoposide and cisplatin(Platinol) used to treat advanced-stage ovarian and testicular germ-cell tumors.[1][2]
Regimen
BBleomycin
EEtoposide
PCisplatin (Platinol)
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y; et al. (2015). "Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour". Eur J Cancer. 51 (3): 340–51. doi:10.1016/j.ejca.2014.12.004. PMID 25559616.